---

---

for   tags : Research   

save search

---

Lam Research Corporation Reports Financial Results for the Quarter Ended March 31, 2024
Published: 2024-04-24 (Crawled : 20:00) - prnewswire.com
LRCX | $884.4 -0.34% -0.34% 1.9M |

Electronic Technology

| Email alert Add to watchlist
corporation research for financial results

---

Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
Published: 2024-04-24 (Crawled : 12:00) - globenewswire.com
AGNPF | $0.089 178.69% 75K |

Health Technology

| 0.0% | O: 0.0% H: 0.0% C: 0.0%
drug conference stroke research for

---

PROCEPT BioRobotics Announces 12 Scientific Research Presentations on Aquablation Therapy for the Treatment of Benign Prostatic Hyperplasia at the 2024 AUA Annual Meeting
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
PRCT A | $52.51 -2.31% -2.36% 520K |

Manufacturing

| 3.65% | O: 0.91% H: 6.09% C: 5.21%
treatment aquablation research biorobotics for meeting therapy

---

HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)
Published: 2024-04-23 (Crawled : 07:00) - prnewswire.com
ONTX | $0.9953 -5.61% 1.3M |

Health Technology

| Email alert Add to watchlist
publication treatment research preclinical for leukemia

---

Sunshine Biopharma's Nora Pharma Receives Health Canada Approval for Niopeg(R), a Biosimilar of Neulasta(R)
Published: 2024-04-19 (Crawled : 14:00) - biospace.com/
SBFM | $0.9263 -23.45% -28.97% 10M |

Professional, Scientific, and T...

| -86.32% | O: -65.59% H: 4.7% C: -24.79%
pharma biosimilar health approval for canada

---

Stemtech Corporation on Track for CEO and Chairman's Goal for Growth and Global Expansion
Published: 2024-04-19 (Crawled : 14:00) - biospace.com/
STEK | $0.0535 -62.89% 1.3M |

n/a

| -14.29% | O: 0.0% H: 0.0% C: -14.29%
ceo corporation expansion global for growth

---

Quebec's INESSS recommends BEYFORTUS for the prevention of RSV for all infants 8 months of age and younger(1)
Published: 2024-04-18 (Crawled : 12:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| 1.4% | O: 0.0% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 2.36% | O: -1.81% H: 0.0% C: 0.0%
beyfortus for rsv

---

Terran Biosciences Granted US Patent for the World’s First New Forms of MDMA, Potentially Clearing the Path to a Future 505(b)(2) Approval
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130 |

Communications

| Email alert Add to watchlist
first patent granted approval for

---

NovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing Expenses
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
NBY | $0.0773 0.39% 0.0% 920K |

Health Technology

| 10.96% | O: 38.7% H: 0.0% C: -20.0%
sales first revenue care pharmaceuticals for

---

Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA(R) (avanafil)
Published: 2024-04-16 (Crawled : 16:00) - biospace.com/
PTPI | $0.635 -6.63% -7.1% 180K |

| -19.55% | O: 9.85% H: 4.63% C: -18.04%
fda positive pharmaceuticals for technology response

---

Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
JAGX | News | $0.1704 1.43% 1.41% 34M |

Health Technology

| 43.1% | O: 26.26% H: 73.2% C: 18.87%
health cancer care for commercial

---

Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run
Published: 2024-04-16 (Crawled : 13:00) - biospace.com/
NBIO | $0.0853 15.32% 140K |

| -16.46% | O: -14.12% H: 0.0% C: -7.1%
research for

---

Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)
Published: 2024-04-15 (Crawled : 13:00) - globenewswire.com
LGVN 4 d | $1.73 -4.95% -5.2% 300K |

| 1.78% | O: 41.42% H: 42.68% C: 22.59%
conference disease association alzheimer’s presentation international research for trial

---

Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
Published: 2024-04-11 (Crawled : 17:00) - biospace.com/
KPRX | $0.504 -13.03% -14.98% 290K |

Manufacturing

| -14.26% | O: 3.23% H: 0.16% C: -1.79%
granted approval pharmaceuticals research for grant trial foundation study

---

Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
APLM | $0.4548 -4.85% -5.1% 170K |

n/a

| -19.01% | O: -2.99% H: 6.9% C: 0.0%
association cancer research for meeting

---

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
MDNAF | $1.14 -17.54% 58K |

n/a

| 27.52% | O: 18.35% H: 13.64% C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study

---

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-09 (Crawled : 21:00) - globenewswire.com
MDNAF | $1.14 -17.54% 58K |

n/a

| 27.52% | O: 18.35% H: 13.64% C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study

---

Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
MURA | $3.595 -1.78% -1.81% 110K |

| -13.67% | O: -1.2% H: 1.94% C: 0.0%
il-18 association cancer research preclinical for meeting il-12

---

Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
RVMD | $35.56 -1.93% -1.97% 1.2M |

Health Technology

| 7.88% | O: 3.0% H: 10.36% C: 7.42%
rmc-6236 publication research for

---

Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
STTK | $9.87 4.0% 3.85% 230K |

Health Technology

| 10.0% | O: -1.11% H: 9.78% C: 9.66%
association presentation cancer research preclinical for meeting

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---